Chinese Drugmaker's IPO Tests a Slumping Biotech Market


Innovent Biologics is going public despite shares of three Chinese biotech firms plunging following recent listing debuts in Hong Kong A Chinese cancer drug developer is pushing ahead with an initial public offering in Hong Kong, despite a global markets rout and the recent poor performance of other biotechnology startups that have listed in the city. Innovent Biologics Inc., a company that has partnered with Eli Lilly & Co.



from Biotech News